Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very odd trading
Just put a "market" order to sell 500 shares (price was at $2.84) it took 4 minutes to get filled!?? usually takes seconds......and I got filled at 2.82 !! then it went back to 2.84!
Thanks....
"LeBistro at 51st and Third"
couldn't find in on google, anyway so many restaurants in Manhattan and even on 51 and third, almost next to each other...
are you sure it is called just "le bistro"?
You are right Esad the tax revenue from cigarettes is huge and it may take some time but when you consider the money spent in treating smokers and cancer related to smoking this would also be a huge saving in healthcare costs. offsetting the tax revenue from cigarettes sales...
The FDA probably knows which side they are on, but when big politic is involved it is anyone guess.......for us it is obvious but I know eventually XXII will be a winner but it may take longer than thought.
On a more personal note I used to be in the restaurant business in NYC for about 25 years and I remember when the smoking ban went into effect, it completely changed my life and health!! (I am a non smoker)..people thought it was gonna be the end of restaurants....well look where we are now!
and in a more personal note my dad died of cancer related to smoking and '
by investing in XXII (and if we make it, somehow I would have my revenge on what killed him) ! long xxii ....
https://untappedcities.com/2015/03/31/today-in-nyc-history-in-2003-mayor-bloombergs-smoking-bans-kicks-in/
Pareteum Announces Registered Direct Offering and Concurrent Private Placement for Gross Proceeds of $6.58M
Today 10:11 AM ET (PR NewsWire)Print
Pareteum Corporation (NYSE American: TEUM), ("Pareteum" or the "Company"), today announced that it agreed to sell an aggregate of 7,151,146 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"). The purchase price per share was $0.92. The shares were offered and are being sold to certain accredited investors in a registered direct offering. Concurrently, the Company agreed to sell in a private placement, warrants to purchase an aggregate of 7,151,146 shares of Common Stock at an exercise price of $1.09 per share with a 5 year term. The Company received gross proceeds from the offering of approximately $6.58 million.
https://mma.prnewswire.com/media/614124/PareteumLogo.jpg
The Company intends to use the net proceeds from the offering for general working capital and corporate purposes and may include debt repayment.
Dawson James Securities, Inc. served as placement agent for the offering.
Thanks esad1
yes it is frustrating but like you said
" the bigger the sample goes the more evidence it gives to the FDA"
I'll keep reminding myself of that while we wait......
I am missing something here??About today's news
"announced today that the Company shipped 2.4 million SPECTRUM(R) research cigarettes for the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH)"
Why are we still shipping SPECTRUM(R) research cigarettes ??
I thought all the research were done already and we were waiting for the
results.........
"A seminal study was recently completed with 22nd Century's SPECTRUM(R) research cigarettes. This independent Phase III study"
Although the results of this highly anticipated clinical trial are still in peer review prior to being published, a principal investigator in the trial, Dr. Dorothy Hatsukami, has already publicly disclosed that an immediate reduction in nicotine is "most likely to lead to less harm."
Old article but still relevant today (IMHO) in any case a great read.
Complete article here
(problem cutting and pasting sorry)
http://www.ibtimes.com/%E2%80%98medical%E2%80%99-marijuana-10-health-benefits-legitimize-legalization-742456
Talking about tax revenue from cigarettes....
For 2015, the most recent reporting year, the NY state lost $1.63 billion because of untaxed sales.....
https://nypost.com/2017/11/11/nyc-is-the-cigarette-smuggling-capital-of-the-us-study/
And in France it is the government raising the price of a cigarette pack to 10 Euro,(about $12) by 2020 to curb smoking.......
https://www.npr.org/2017/10/05/555796355/french-cigarette-sellers-protest-government-price-hike
Yes great C.C and I urge everybody to read it entirely, it is long but worth it and it will answer any Q you may have about the Cie and erase any doubts you may have about its future…… Because there's multiple avenues here, these guys are going in the million different directions and I just see a lot of potential near and far.
Has a Long term investor I am very excited and looking forward to a lot of exciting things that will happen in the next 2 to 24 months.
Conspiracy Theory
So this guy was an insider working for bigT and now working for XXII (against BT) could he be a Trojan horse sent by BT and infiltrated xxii to derail or slow our progress??
I know I know far fetch lol but one must wonder no?
Thank you so much Alien42
I have to admit I only researched their website where the patents are mentioned but there is no link attached to it...I should have done a better DD.
I feel better now about my investment but the lack of institutional investors is still troublesome..to me...
Question to the board here..
New to PVHO I like the technology but after doing some research couldn't find that they have any patents on their technology.....any thoughts??
Also why is there NO institutional investors??
I do own some penny stocks, cheaper than PVHO and they do have some institutional investors..
Thanks for any answer....
So was it just a big F.... waste of time ? and why do it then?
"I think when the deal was drawn up some probably knew that BAT would never exercise it."
Thanks for posting this .
Interesting to see some background and where it comes from ...
It makes the discussion more relevant .
BASF signs 3D bioprinting cosmetics deal with Poietis
(ONVO mentioned but not in a good way)
Since September 2016 Poietis has been working with L’Oréal cosmetics to develop 3D bioprinted hair. Biotechnology competitor Organovo has also been working with the French cosmetics giant in efforts to fabricate skin tissue. However a sharp decline in Organovo’s share-price and having a sizeable proportion of their workforce redundant has added to concerns about the company
Link to the article
https://3dprintingindustry.com/news/basf-signs-3d-bioprinting-cosmetics-deal-poeitis-123313/
Even better chart look at Organovo (ONVO)
in 2 weeks it went from $2.25 (10.04.17) to $1.35 (10.19.17) on high volume and now going back up ($1.60) they have a great technology .
SHU Portfolio: And Now For Something Completely Speculative
Oct. 19, 2017 XXII
22nd Century Group
We have written before about this company, the owner of an interesting IP that allows them to grow tobacco with various levels of nicotine, from virtually zero to a heavy load.
This opens up the possibility to fabricate cigarettes which are either hardly addictive ("Brand A" very low nicotine) or not addictive at all, and/or use these as a smoking cessation device (X-22 smoking cessation product).
It might surprise some but they could also load cigarettes with lots of nicotine (their "Brand B" product) so you smoke less and get less of the harmful tar and other chemicals. There are a couple of fairly recent big breakthroughs.
FDA intents to regulate nicotine levels
The FDA has issued its intention to regulate nicotine. While this is a long-term affair, it's potentially an enormous boost to the company. From the FDA PR on what is at stake:
“The overwhelming amount of death and disease attributable to tobacco is caused by addiction to cigarettes – the only legal consumer product that, when used as intended, will kill half of all long-term users,” said FDA Commissioner Scott Gottlieb, M.D. “Unless we change course, 5.6 million young people alive today will die prematurely later in life from tobacco use.
The FDA isn't going to regulate nicotine levels just like that. They are going to start a 'dialogue' (our emphasis):
The FDA plans to begin a public dialogue about lowering nicotine levels in combustible cigarettes to non-addictive levels through achievable product standards. The agency intends to issue an Advance Notice of Proposed Rulemaking (ANPRM) to seek input on the potential public health benefits and any possible adverse effects of lowering nicotine in cigarettes... The FDA is committed to encouraging innovations that have the potential to make a notable public health difference and inform policies and efforts that will best protect kids and help smokers quit cigarettes. To make this effort successful, the agency intends to extend timelines to submit tobacco product review applications for newly regulated tobacco products that were on the market as of Aug. 8, 2016. This action will afford the agency time to explore clear and meaningful measures to make tobacco products less toxic, appealing and addictive.
XXII could be one of the biggest beneficiaries of this FDA move if this results in regulating nicotine levels in cigarettes.
Smoking cessation X-22
There is also progress with their smoking cessation product X-22, which is simply their Spectrum research cigarettes with various levels of nicotine. Yet another clinical study (this one Phase III) seems to have been a success. From the company PR:
22nd Century was the exclusive provider of the Very Low Nicotine and other SPECTRUM research cigarettes that were used in Dr. Hatsukami’s 1,250-participant trial and in more than 16 other clinical trials... Though the details of Dr. Hatsukami’s phase III study are still under peer review, Dr. Hatsukami divulged the answer to the study’s core question of whether an immediate or a gradual reduction in nicotine is the best approach. Dr. Hatsukami clearly and confidently declared in her panel presentation at the Vermont Conference that “an immediate approach [to nicotine reduction] is most likely to lead to less harm.” Further, Dr. Hatsukami pointed out that the study data indicates compensatory smoking is less likely to occur with an immediate reduction in nicotine, and that the there was a “greater likelihood of more rapid smoking cessation” with the immediate approach to nicotine reduction.
Modified Risk Tobacco Products application (MRTP)
The company is also moving forward with their application (here in full) for Brand A cigarettes (containing 95% less nicotine than average cigarettes) to qualify as an MRPT product.
The problem today is that while the company can (and does) produce low nicotine cigarettes, it cannot market them as such, so achieving MRTP status would be a big boost. Here is the status, from the Q2 earnings PR:
In June 2017, 22nd Century met twice with the U.S. Food and Drug Administration (“FDA”) to advance the Company’s efforts to gain regulatory approval for its novel products. On June 15, 2017, 22nd Century met with the FDA’s Center for Tobacco Products (“CTP”) to discuss the Company’s BRAND A Modified Risk Tobacco Product (“MRTP”) application for an over-the-counter cigarette with labeling that discloses that the product contains 95% less nicotine than conventional tobacco cigarettes. Based on guidance received from the FDA/CTP at that meeting, 22nd Century is working to resubmit its MRTP application with additional consumer perception data pertaining to the product, together with information from already completed clinical studies using the Company’s Very Low Nicotine (“VLN”) tobacco cigarettes and related scientific data. In 2018, 22nd Century intends to submit its revised MRTP application for the world’s lowest nicotine tobacco cigarette.
Finances
Lest we forget, the company is already selling cigarettes (and cigars) and sales are growing at a promising pace. From the Q2 earnings PR:
sales of the Company’s conventional products continue to grow impressively. Second quarter results show that 22nd Century is already experiencing the benefits of newly signed manufacturing agreements. Revenue for the second quarter of 2017 increased to approximately $3.9 Million – a 37.8% increase over the revenues for the second quarter of 2016 and the highest quarterly revenue in the Company’s history. 22nd Century projects that year-end revenue will exceed $16 Million – a new record for the Company. In addition to climbing revenues, the Company currently has approximately $17.8 Million in cash, the highest amount of cash on hand in the history of the Company. 22nd Century’s cash reserves are sufficient to meet all regular operating expenses through at least March 2019.
But despite that revenue progress, there was still a loss ($3.35M) almost as large as the revenue itself. This isn't turning a profit anytime soon. The company did argue that its factory, which gained a greatly expanded contract manufacturing deal earlier this year, will be cash flow positive and generate revenues over $20M.
Risks
As with any small-cap stock, the risks are also considerable. For instance, they received a setback last year in Europe. From the year-end report:
For example, since the spring of 2016, European Union law no longer permits us to disclose the nicotine yield on our MAGIC cigarette packaging. And so, rather than continuing to expand MAGIC sales without the ability to disclose the remarkably low nicotine yield of our Very Low Nicotine MAGIC cigarettes, we have opted to first secure European regulatory approvals for our Very Low Nicotine cigarettes.
That is why we lost some interest in the stock, as the company was out with a promising start with these MAGIC cigarettes and we argued that the revenue growth would be essential to finance all the regulatory and clinical work without diluting the shares to oblivion.
However, dilution seems to have been taken care of for the foreseeable future with a $54M (20.57M shares) offering at $2.625 which brings their cash balance to some $70M+ (the company had $17.8M in cash at the end of Q2).
That should be enough for the next five years or so, at least according to management. The pleasant surprise was that this offering didn't come with the usual deluge of warrants attached, but mind you, there are still plenty of the latter around as a result of previous offerings.
You might note that our purchase for the SHU portfolio of 2000 shares of XXII on October 18 (per StockTalks) was just five cents above this offering price (at the time of the offer, the shares traded well above $3). Basically, we're riding with those institutions that bought the offer.
Nevertheless, the dilution is considerable and is set to continue as a result of outstanding warrants and compensation policies:
The company has a strong intellectual property portfolio of more than 200 patents (and 50+ pending) on regulating nicotine levels through genetic engineering in tobacco plants and regulating THC levels in cannabis.
American Tobacco (NYSEMKT:BTI)
And then there is this, from a September 25 company PR:
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, is pleased to announce that the 2013 Research License and Commercial Option Agreement between the Company and British American Tobacco (Investments) Limited (“BAT”) is now finished. BAT no longer has rights to any intellectual property or other assets of 22nd Century; 22nd Century is now again in sole control of the Company’s highly disruptive intellectual property portfolio relating to the ability to grow patent-protected Very Low Nicotine tobacco plants. Accordingly, the Company has recommenced discussions with global tobacco companies and international pharmaceutical companies that have expressed strong interest in a business relationship with 22nd Century but were, until now, unable to enter into a licensing agreement with 22nd Century due to restrictive covenants contained in the BAT agreement.
Quite frankly, we wondered for quite some time what happened to this and we have distinctly mixed feelings about the end of their deal with BAT. It is a little curious that BAT didn't want to proceed. They could have exchanged what was an R&D license into a commercial license, but apparently, chose not to do so.
Curious especially in the light of the recent FDA move setting some sort of a timeline for regulating nicotine levels in cigarettes. It isn't that this is easy to achieve that. Here is Bloomberg about the difficulties of producing low-nicotine cigarettes:
Producing a cigarette with low levels of nicotine, the addictive stimulant in cigarettes, has been a challenge for the industry since as far back as the 1960s. Large tobacco companies such as Philip Morris International Inc. have tried their hand at it and failed...
Previous efforts to make low-nicotine cigarettes failed in part because tobacco varieties developed to meet the goal had lower yields, making them less desirable for farmers. They also tended not to have tastes or smells deemed desirable by industry and consumers. Low-nicotine plants can also attract pests that normal tobacco wouldn’t. “Nicotine is a natural insecticide, if you will, so the lower the levels of nicotine, the less resistant the plants are to pests,” Sicignano said. That raises growing costs. Genetic modification has emerged as a shortcut to some of the challenges, said Ramsey Lewis, a biotechnology researcher at North Carolina State University, home to the U.S. repository of tobacco strains. Yet those advances come with drawbacks as well, he said.
“Living things are complex,” he said. “When you produce a lower nicotine variety using a genetics approach, other characteristics of the plant can change the plant, which may be bad for growers or undesirable for the industry.” 22nd Century uses both approaches -- some of its low-nicotine varieties use lab-based genetic modification, while others are bred with traditional techniques. It’s licensed its nicotine-altering technology to British American Tobacco in a deal worth as much as $14 million.
There is little doubt that XXII is a leading contender, probably even the leading contender in the march towards low-nicotine cigarettes, but of course, we don't know what's going on in the labs of BAT (or other big tobacco companies).
The upside is that XXII now has their hands free to enter into other commercial agreements, and apparently, there is no lack of interest, at least according to management. But we have to wait and see what becomes of this.
Conclusion
22nd Century provides an interesting play with several possibilities to monetize their vast intellectual property. It has a plant that does mainly contract manufacturing producing growing revenues and is expected to be cash flow positive next year.
It is applying MRTP status for its Brand A, which would give it a significant marketing advantage if successful. It is also applying for regulatory approval for its smoking cessation product X-22 which works very well according to various clinical trials.
The jackpot is if the FDA starts mandating lower nicotine levels. This isn't likely to happen anytime soon, but the chances have significantly increased after the FDA has announced its intentions.
Given that after the last share issue and the favorable development of its plant, dilution is going to slow down, we think the recent retreat in the share price was a good opportunity to start an initial position.
And we haven't even touched on the opportunities of their cannabis IP (they have similar genetic methods to regulate the levels of THC in cannabis).
But against that, there are numerous risks. None of their products have regulatory approval, and this could take significant time to achieve that, if at all. The company is still burning significant amounts of cash.
Disclosure: I am/we are long DSNY, XXII, INSG
Link to the entire article
https://seekingalpha.com/article/4114558-shu-portfolio-now-something-completely-speculative?ifp=0
Link to the news
22nd Century Completes Successful Hemp Field Trials with University of Virginia
http://www.businesswire.com/news/home/20171019005482/en/22nd-Century-Completes-Successful-Hemp-Field-Trials
22nd Century Group 13G Filing From CVI Investments Shows 5.7% Stake
https://www.benzinga.com/news/17/10/10186468/22nd-century-group-13g-filing-from-cvi-investments-shows-5-7-stake
What A Free Marijuana Trade With Mexico Would Look Like: Former President Vicente Fox To Speak In Phoenix Oct. 14
"With the NAFTA, about 60 percent of tomatoes consumed in the U.S. come from Mexico, where it’s easier and cheaper to grow, Downing said. “Cannabis is a comparable crop and Mr. Fox understands that, eventually, marijuana will be grown in Mexico and exported legally to the United States"
https://www.benzinga.com/news/17/10/10152258/what-a-free-marijuana-trade-with-mexico-would-look-like-former-president-vicente
Here is the link
"22nd Century Group Could Win Big From FDA Plan To Reduce Nicotine In Cigarettes"
https://seekingalpha.com/article/4104282-22nd-century-group-win-big-fda-plan-reduce-nicotine-cigarettes
It's Official: A Pack Of Cigarettes Now Costs $13 In NYC
"Even though tobacco is a leading cause of premature death across the country, Big Tobacco will stop at nothing to hook people on these deadly products,"
http://gothamist.com/2017/08/28/nyc_most_expensive_cigarettes.php?utm_source=Manhattan&utm_campaign=86c065d358-Mailchimp-NYC&utm_medium=email&utm_term=0_7456974fe2-86c065d358-132617029
(It still costs 40% to borrow )
For what it's worth I am a long term holder on another Co (MVIS)and there were offering high % to borrow the stock so they could short the hell out.. stock was at around $2.50 Turned out the Co did an offering at 2.10 !! ...there is always someone that know something before main street...
Not sure why this article focus so much on Lexaria Bioscience Corp's technology ( no much info out there on this Cie beside their website).
Anyway why going with their technology when we Have XXII that can just lower or eliminate nicotine all together.
Awesome Thanks
Do XXII grow enough tobacco to be able to supply them all ??
" WE are going to sell tobacco to cigarette companies for their FDA mandated use in camels, marlboros or whatever"
Thanks Noname for the article and I believe it hasn't been posted yet.
we are getting more exposure every day...
Can't wait to see how the stock will react tomorrow morning but last I checked it was up .15 AH
Also learned something new about the Cie.
"22nd Century, based in Clarence, N.Y., in 2013 bought the cigarette-manufacturing equipment of defunct Renegade Tobacco Co. for $3.22 million in a bankruptcy proceeding"
They said"
Indeed, in assessing the usefulness of reducing nicotine levels in cigarettes, we need to consider the unintended consequences that mildly reducing nicotine levels may lead to higher per capita consumption as smokers look for an offset"
Well I say then it is a win win situation for both XXII and big tabacco!!
Why the big 24 hours gap between the earnings yesterday and the CC today ?
Is it normal?
They should buy XXII instead
But Hey one less player
British American Tobacco Plc sold the second-largest bond deal of the year to finance its purchase of the portion of Reynolds American Inc. that it didn’t already own.
The proceeds will help permanently finance BAT’s 42 billion-pound ($55 billion) purchase of the remaining shares of Reynolds, a deal that will propel BAT to the top position in tobacco-related products globally
https://www.bloomberg.com/news/articles/2017-08-08/bat-plans-one-of-2017-s-biggest-bond-deals-for-reynolds-purchase
Great update!
FDA's Plan to Lower Nicotine in Cigarettes Has Captured the Attention of Regulators and Public Health Experts Around the World
http://www.businesswire.com/news/home/20170809005925/en/FDAs-Plan-Nicotine-Cigarettes-Captured-Attention-Regulators
I understand what shorting is, what I don't understand is why on earth someone would pay such a high %fee to short this stock?? what do they have to gain? do they know something we don't? it is a very dangerous game they are playing, just move on and short another stock, there are plenty overvalued stocks out there I am sure.
Now the only answer I could come up is that they have two different accounts, one to short the stock so the price goes down and buy and accumulate the same stock but cheaper on the over account..
Is it really what is happening??
Question!
Does XXII needs to reach the $5 threshold that makes it accessible to (some)institutional investors; thus, as the theory goes, the stock will continue to climb after opening to new buyers. Since stocks below $5 are considered penny stocks or micro cap, and many large funds are prohibited from investing in them.
Thanks
I have enough shares left that I am not selling for a long time, like I said I bought those around .90 and always good to take a little profit.
besides I needed to reduce my margin...
Just sold 500 share at the 2.07 top (bought at .92)anyway my Q is why it toke 5 trades to sell only 500 shares? if everybody is buying it should have been sold at 2.05 right away no??what am I missing?
anyway explanation? Thanks in advance for educating me..
OTOH I missed the new top of 1.13 but still long 6500 shares
and DTAmeritrade went down just as I was selling my shares...back up now!
08/04/2017 09:59:57 Sold 100 XXII @ 2.053
08/04/2017 09:59:57 Sold 150 XXII @ 2.055
08/04/2017 09:59:57 Sold 100 XXII @ 2.055
08/04/2017 09:59:57 Sold 100 XXII @ 2.053
08/04/2017 09:59:57 Sold 50 XXII @ 2.05
Gotta love this!
A Cannabis Wonderland? This Company Bought A Whole Town In California To Create A Marijuana Tourism Destination
https://www.benzinga.com/news/17/08/9871855/a-cannabis-wonderland-this-company-bought-a-whole-town-in-california-to-create-a-
Great indeed but this part always bother me....
"Health advocates who want tougher action against cigarettes aren’t celebrating the announcement; they say the process mapped out by the FDA could take years and express doubts the agency will ultimately follow through.
We’re concerned about how long a product standard on reducing the addictiveness of cigarettes is going to take based on the process outlined on Friday,” said Erika Sward, a spokeswoman for the American Lung Association.
We’re concerned about how long a product standard on reducing the addictiveness of cigarettes is going to take based on the process outlined on Friday,” said Erika Sward, a spokeswoman for the American Lung Association.
Experts say any regulation, even down the road, is likely to be tied up for years in a legal fight with industry"
"tobacco is a huge source of tax revenue and the FDA knows that and will tread lightly"
Yes and when Marijuana becomes a new and huge source of tax revenue this way of thinking will switch from tobacco to cannabis.
Also "Tobacco companies having lobbyists and lawyers"
Same here when Marijuana business starts growing exponentially they will have lobbyists and lawyers and first thing they will do is pay out/finance politics!
Politics need to finance their campaigns they don't care where the money comes from as long as it comes in..
all IMHO